Client MOMA Therapeutics Establishes Bayer Collaboration and License Agreement in Oncology

In The News
October 9, 2024

Ropes & Gray advised MOMA Therapeutics in a collaboration and exclusive license agreement with Bayer to develop and commercialize a small molecule oncology program based on MOMA’s proprietary KNOMATIC platform. The collaboration was announced on October 8.

Under the agreement, Bayer will be responsible for completing further preclinical, development and commercial activities. MOMA will receive an upfront payment and collaboration fee and is eligible to receive near-term discovery, development, and commercial milestones as well as tiered royalties on net sales.

MOMA Therapeutics was represented by life sciences licensing partner Hannah England and life sciences associate Ian Nilsen.